Case Report| Volume 274, P26-29, June 2023

Download started.


Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement


      • t(8;22)/BCR-FGFR1 rearrangement is a rare genetic abnormality identified in a case of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
      • Sorafenib in combination with Azacytidine could be effective in patients with sole t(8;22)/BCR-FGFR1 rearrangement as complete haematological response was observed in our case.
      • Combination of Sorafenib and Azacytidine treatment can help in management of patients with sole t(8;22)/BCR-FGFR1 rearrangement where targeted therapy or HSCT transplantation is not possible.


      The sole t(8;22)(p11.2;q11.2)/BCR- FGFR1 chromosomal abnormality formerly known as aCML is an extremely rare disease entity with a history of rapid progression. Though patients resemble phenotypically chronic myeloid leukemia, the treatment of patients with sole BCR-FGFR1 rearrangement are still challenging for clinicians due to rapid progressive nature and unavailability of uniform treatment guidelines. In present case study, we describe a case of myeloid neoplasm with sole chromosomal abnormality of t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement which is successfully managed by Sorafenib with Azacitidine. Hence our case report suggests that combination of Sorafenib and Azacitidine treatment is effective in sole BCR-FGFR1 rearrangement, however this combination therapy should be studied in large clinical trials.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Galton DA.
        Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.
        Leuk Lymphoma. 1992 Jan 1; 7: 343-350
        • Alaggio R
        • Amador C
        • Anagnostopoulos I
        • Attygalle AD
        • Araujo IB
        • Berti E
        • et al.
        The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms.
        Leukemia. Jul 2022; 36: 1720-1748
        • Raess P.W.
        Myelodysplastic/myeloproliferative neoplasms.
        Atlas Genet Cytogenet Oncol Haematol. 2018; 22 (398–2)
        • Bennett JM
        • Catovsky D
        • Daniel MT
        • Flandrin G
        • Galton DA
        • Gralnick H
        • et al.
        The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French-American-British Cooperative Leukaemia Group.
        Br J Haematol. Aug 1994; 87: 746-754
        • Tong X
        • Li J
        • Zhou Z
        • Zheng D
        • Liu J
        • Su C.
        Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
        Leuk Lymphoma. Jun 3 2015; 56: 1911-1913
        • Jiang H
        • Wu Z
        • Ren LI
        • Tao D
        • Tong H.
        Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.
        Oncol Lett. Jan 1 2016; 11: 689-692
        • Kreil S
        • Adès L
        • Bommer M
        • Stegelmann F
        • Ethell ME
        • Lubking A
        • et al.
        Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes.
        Blood. Dec 3 2015; 126: 2812
        • Iyer MK
        • Chinnaiyan AM
        • Maher CA.
        ChimeraScan: a tool for identifying chimeric transcription in sequencing data.
        Bioinformatics. Oct 15 2011; 27: 2903-2904
        • Nicorici D
        • Şatalan M
        • Edgren H
        • Kangaspeska S
        • Murumägi A
        • Kallioniemi O
        • et al.
        FusionCatcher–a tool for finding somatic fusion genes in paired-end RNA-sequencing data.
        Biorxiv. Jan 1 2014; 011650
        • Davidson NM
        • Majewski IJ
        • Oshlack A.
        JAFFA: High sensitivity transcriptome-focused fusion gene detection.
        Genome medicine. Dec 2015; 7: 1-2
        • Ricci F
        • Balducci S
        • Guerrini F
        • Grassi S
        • Ciabatti E
        • Baratè C
        • et al.
        Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation.
        Clinical Hematology International. Sep 2020; 2: 129
        • Peiris MN
        • Li F
        • Donoghue DJ.
        BCR: a promiscuous fusion partner in hematopoietic disorders.
        Oncotarget. Apr 12 2019; 10: 2738
        • Richebourg S
        • Theisen O
        • Plantier I
        • Parry A
        • Soenen-Cornu V
        • Lepelley P
        • et al.
        Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia.
        Genes Chromosomes Cancer. Oct 2008; 47: 915-918
        • Montenegro-Garreaud X
        • Miranda RN
        • Reynolds A
        • Tang G
        • Wang SA
        • Yabe M
        • et al.
        Myeloproliferative neoplasms with t (8; 22)(p11. 2; q11. 2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
        Human pathology. Jul 1 2017; 65: 147-156
        • Chen X
        • Huang L
        • Zheng C
        • Wang Z.
        A case of a patient characterized by t (8; 22)(p11; q11) and BCR/FGFR1 fusion gene, who was successfully treated with haploidentical hematopoietic stem cell transplantation.
        Hematology. Jan 1 2021; 26: 691-696
        • Washburn E
        • Bayerl MG
        • Ketterling RP
        • Malysz J.
        A rare case of atypical chronic myeloid leukemia associated with t(8; 22)(p11.2; q11.2)/BCR-FGFR1 rearrangement: A case report and literature review.
        Cancer Genet. Nov 1 2021; 258: 69-73
        • Hausmann H
        • Bhatt VR
        • Yuan J
        • Maness LJ
        • Ganti AK.
        Activity of single-agent decitabine in atypical chronic myeloid leukemia.
        Journal of Oncology Pharmacy Practice. Dec 2016; 22: 790-794
        • Onida F
        • de Wreede LC
        • van Biezen A
        • Eikema DJ
        • Byrne JL
        • Iori AP
        • et al.
        Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
        Br J Haematol. Jun 2017; 177: 759-765
        • inhibitors Katoh M.FGFR
        Effects on cancer cells, tumor microenvironment and whole-body homeostasis.
        Int J Mol Med. Jul 1 2016; 38: 3-15
        • Landberg N
        • Dreimane A
        • Rissler M
        • Billström R
        • Ågerstam H.
        Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
        Eur J Haematol. Nov 2017; 99: 442-448
        • Jain L
        • Woo S
        • Gardner ER
        • Dahut WL
        • Kohn EC
        • Kummar S
        • et al.
        Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
        Br J Clin Pharmacol. Aug 2011; 72: 294-305
      1. Al-jamal HA, Jusoh SM, Hassan R, Farid M. Azacytidine Enhances Efficacy of Tyrosine Kinase Inhibitors in Aml Cells.

        • Marumo A
        • Mizuki T
        • Tanosaki S.
        Atypical chronic myeloid leukemia achieving good response with azacitidine.
        Indian J Cancer. Oct 1 2019; 56: 354
        • Langabeer SE
        • Comerford CM
        • Quinn J
        • Murphy PT.
        Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.
        J Clin Pathol. Dec 1 2017; 70: 1089